Terms: = Pancreatic cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Staging
5 results:
1. [Ductal adenocarcinoma of the pancreas: subtypes and molecular pathology].
Schlitter AM; Konukiewitz B; Kasajima A; Reichert M; Klöppel G
Pathologe; 2021 Sep; 42(5):464-471. PubMed ID: 34402977
[TBL] [Abstract] [Full Text] [Related]
2. Development and validation of a novel competing risk model for predicting survival of esophagogastric junction adenocarcinoma: a SEER population-based study and external validation.
Wang T; Wu Y; Zhou H; Wu C; Zhang X; Chen Y; Zhao D
BMC Gastroenterol; 2021 Jan; 21(1):38. PubMed ID: 33499821
[TBL] [Abstract] [Full Text] [Related]
3. The Unmet Needs of the Diagnosis, staging, and Treatment of Gastrointestinal Tumors.
Halama N; Haberkorn U
Semin Nucl Med; 2020 Sep; 50(5):389-398. PubMed ID: 32768003
[TBL] [Abstract] [Full Text] [Related]
4. [Viability of extended distal pancreatectomy for pancreatic adenocarcinoma of the body or tail].
Guo ZH; Tan CL; Chen HY; Ke NW; Li A; Liu XB
Zhonghua Wai Ke Za Zhi; 2016 Mar; 54(3):201-5. PubMed ID: 26932889
[TBL] [Abstract] [Full Text] [Related]
5. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract] [Full Text] [Related]
